113 related articles for article (PubMed ID: 29788737)
1. Diagnosis for carcinoma of unknown primary site with the aid of simple PCR tests: a single-center experience.
Suspitsin E; Yanus G; Imyanitov E
Neoplasma; 2018 Mar; 65(3):461-468. PubMed ID: 29788737
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling.
Oien KA; Dennis JL
Ann Oncol; 2012 Sep; 23 Suppl 10():x271-7. PubMed ID: 22987975
[TBL] [Abstract][Full Text] [Related]
3. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
Greco FA
Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma of unknown primary (CUP); some considerations about pathogenesis and diagnostic strategy, particularly focusing on CUPS pertaining to the Urology.
Alberti C
G Chir; 2012; 33(1-2):41-6. PubMed ID: 22357439
[TBL] [Abstract][Full Text] [Related]
5. CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2.
Altree-Tacha D; Tyrrell J; Haas T
Arch Pathol Lab Med; 2017 Jan; 141(1):144-150. PubMed ID: 28029907
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of metastatic neoplasms with unknown primary.
Bochtler T; Löffler H; Krämer A
Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
[TBL] [Abstract][Full Text] [Related]
7. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
Dennis JL; Hvidsten TR; Wit EC; Komorowski J; Bell AK; Downie I; Mooney J; Verbeke C; Bellamy C; Keith WN; Oien KA
Clin Cancer Res; 2005 May; 11(10):3766-72. PubMed ID: 15897574
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
Hainsworth JD; Greco FA
Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
[TBL] [Abstract][Full Text] [Related]
11. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
[TBL] [Abstract][Full Text] [Related]
12. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
[TBL] [Abstract][Full Text] [Related]
13. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
Greco FA; Hainsworth JD
Clin Genitourin Cancer; 2018 Aug; 16(4):e893-e898. PubMed ID: 29610002
[TBL] [Abstract][Full Text] [Related]
14. Metastasis of unknown origin.
Haskell CM; Cochran AJ; Barsky SH; Steckel RJ
Curr Probl Cancer; 1988; 12(1):5-58. PubMed ID: 3067982
[TBL] [Abstract][Full Text] [Related]
15. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
[TBL] [Abstract][Full Text] [Related]
16. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
[TBL] [Abstract][Full Text] [Related]
18. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site.
Brown RW; Campagna LB; Dunn JK; Cagle PT
Am J Clin Pathol; 1997 Jan; 107(1):12-9. PubMed ID: 8980361
[TBL] [Abstract][Full Text] [Related]
20. CUP: looking for a missing primary site and its biology.
Pentheroudakis G
Ann Oncol; 2012 Sep; 23 Suppl 10():x278-81. PubMed ID: 22987976
[No Abstract] [Full Text] [Related]
[Next] [New Search]
